Kemwell AB has signed an agreement with Mercury Pharma Group Ltd. for the manufacture of pharmaceuticals at its new production facility in Uppsala. The agreement covers the manufacture of tablets and release and distribution of products to Great Britain and Ireland.
 
“This agreement shows that we are indeed competitive in Sweden in production. Our new modern facility gives great opportunities for pharmaceutical manufacture in collaboration with both new and existing customers,” said Kemwell’s chief executive officer, Agneta Bergvall.
 
Kemwell is a CMO with production facilities in both India and Sweden. The company was established through the acquisition of a facility from Pfizer, with manufacturing capabilities for tablets, suppositories and capsules.